Halozyme Therapeutics Inc HALO

US Biotechnology

$82.54 ▼ -0.91% ($-0.76)

📅 Earnings This Week

Open $83.19

Prev Close $83.30

Day Range $81.50 – $83.27

52W Range $58.53 – $84.44

Market Cap $9.79B

P/E (TTM) 28.07

Beta 0.86

EPS (TTM) $2.78

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2003-01-30
Shares Out.	118,610,000
Website	halozyme.com/ ↗
Phone	13026587581
Employees	423
Revenue	$376.7M
Gross Profit	$297.5M
Net Income	$150.0M
Free Cash Flow	$667.7M
Total Assets	$2.67B
Total Liabilities	$2.45B
Equity	$219.6M

About Halozyme Therapeutics Inc

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics Inc is a publicly traded company under the ticker symbol HALO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.